<DOC>
	<DOCNO>NCT00213655</DOCNO>
	<brief_summary>Evaluation maintenance BCG immunotherapy ( dose 27 mg ) superficial bladder tumor . Two randomized arm ( every 3 6 month ) study population 300 patient .</brief_summary>
	<brief_title>URO-BCG-4 : Bladder Tumors Immunotherapy</brief_title>
	<detailed_description>BCG maintenance immunotherapy 1/3 dose : 27 mg two randomized arm : 3 6 month 36 month clinical side effect accord OMS score efficacy regard recurrence : cytology cystoscopy PSA , leucocyturia N-ramp gene evaluation</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Ta T1 bladder tumor BCG contraindication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>